Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial

Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patients showed disease progression, they received subsequent novel therapies t...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Andrew, Samoilova, Olga, Chng, Wee‐Joo, Labotka, Richard, Li, Cong, Wu, Kwang‐Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713050/
https://www.ncbi.nlm.nih.gov/pubmed/36467842
http://dx.doi.org/10.1002/jha2.548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713050/
https://www.ncbi.nlm.nih.gov/pubmed/36467842
http://dx.doi.org/10.1002/jha2.548

Ejemplares similares